Toth Financial Advisory Corp Purchases New Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Toth Financial Advisory Corp purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the first quarter, HoldingsChannel.com reports. The fund purchased 5,335 shares of the biotechnology company’s stock, valued at approximately $832,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. GAMMA Investing LLC raised its stake in Ascendis Pharma A/S by 15,593.0% in the first quarter. GAMMA Investing LLC now owns 91,490 shares of the biotechnology company’s stock valued at $142,600,000 after purchasing an additional 90,907 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at about $174,000. Woodline Partners LP raised its stake in Ascendis Pharma A/S by 35.2% in the fourth quarter. Woodline Partners LP now owns 317,642 shares of the biotechnology company’s stock valued at $43,730,000 after purchasing an additional 82,624 shares in the last quarter. Zimmer Partners LP raised its stake in Ascendis Pharma A/S by 24.2% in the fourth quarter. Zimmer Partners LP now owns 96,900 shares of the biotechnology company’s stock valued at $13,340,000 after purchasing an additional 18,900 shares in the last quarter. Finally, Vestal Point Capital LP raised its stake in Ascendis Pharma A/S by 108.0% in the fourth quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock valued at $71,588,000 after purchasing an additional 270,000 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have issued reports on ASND. Morgan Stanley upgraded Ascendis Pharma A/S from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $180.00 to $250.00 in a research report on Monday, May 5th. Royal Bank of Canada lifted their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, May 12th. JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an “overweight” rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus price target of $217.73.

Ascendis Pharma A/S Trading Up 0.1%

NASDAQ:ASND opened at $173.15 on Tuesday. The stock has a market cap of $10.56 billion, a P/E ratio of -24.39 and a beta of 0.37. The stock’s 50-day moving average is $159.37 and its 200-day moving average is $147.11. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.